Search Results
Your search for Blood matches 4627 pages
Showing 1501 - 1550My Inherited Condition Has Led to a Life and Career I Love
My father died of thymic cancer when I was 14, and that’s when I decided to become an oncologist. Ironically, the first patient I diagnosed with cancer was me. In 2009, during my first week of training in hematology/oncology at the Mayo Clinic, I began having severe abdominal pain, which had...
Cedars-Sinai Announces Addition of New Researchers, Physicians to Faculty
In a news release issued earlier this month, Dan Theodorescu, MD, PhD, Director of Cedars-Sinai Cancer Center in Los Angeles, welcomed several new researchers and physicians to the faculty of the institution. “I am very grateful to the institutional leadership that our efforts to expand the breadth ...
High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
Astragalus
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on the...
Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?
Patients receiving care for advanced cancer based on the recommendations of a molecular tumor board were more likely to survive or experience a longer period without disease progression, according to results from a study published by Kato et al in Nature Communications. Razelle Kurzrock, MD,...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the fight against blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton, ...
Pilot Study Finds Liquid Biopsy Delivers Results Faster Than Tissue Biopsy
A pilot study comparing liquid biopsy with tissue-based testing showed that liquid biopsy delivered results approximately 10 days faster than tissue biopsy, according to research presented by Nir Peled, MD, PhD, and colleagues at the International Association for the Study of Lung Cancer (IASLC)...
Liquid Biopsy May Be a Timely and Effective Testing Method for Patients With NSCLC: Findings From Canada
Next-generation sequencing of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing in patients with advanced non–small cell lung cancer (NSCLC) and may also be faster and less expensive than standard tissue profiling, according to research presented by Natasha B. Leighl, ...
Novel Small-Molecule Inhibitor Surufatinib for Advanced Extrapancreatic Neuroendocrine Tumors
In the Chinese phase III SANET-ep trial reported in The Lancet Oncology, Xu et al found that surufatinib improved progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors. Surufatinib is a novel small-molecule inhibitor that targets VEGFR-1, VEGFR-2,...
First-in-Class Human IgG4 Monoclonal Antibody Shows Activity Alone and Combined With Pembrolizumab in Advanced Solid Tumors
MK-4830—a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific anti–immunoglobulin-like transcript 4 (ILT4) receptor—administered either as a single agent or in combination with pembrolizumab was well tolerated and showed activity in heavily pretreated patients with...
Is ctDNA Effective in Detecting Genomic Alterations in Patients With Metastatic Kidney Cancer?
Circulating tumor DNA (ctDNA) analysis is a minimally invasive genomic assessment tool utilizing targeted next-generation sequencing of peripheral blood. At the ESMO Virtual Congress 2020, Zengin et al reported genomic results from a large cohort of patients with metastatic renal cell carcinoma...
Leukemia & Lymphoma Society Launches First Clinical Trial in Patients With Hematologic Malignancy and COVID-19
In response to studies showing that between 30% and 60% of patients with blood cancer are at risk of death if infected with COVID-19 compared with patients who are cancer-free, the Leukemia & Lymphoma Society (LLS) has announced its launch of the first clinical trial dedicated solely to this...
Study Finds Recent-Onset Diabetes With Unintentional Weight Loss Linked to Increased Risk of Pancreatic Cancer
A large cohort study with close to 160,000 men and women reported that “recent-onset diabetes accompanied by weight loss was associated with a substantial increase in risk for pancreatic cancer and may represent a high-risk group in the general population for whom early detection strategies would...
Conquer Cancer Collaborates With Israel Cancer Research Fund for Career Development Award in Israel
Conquer Cancer®, the ASCO Foundation has joined forces with the Israel Cancer Research Fund (ICRF) to grant a 2020 Career Development Award (CDA) to a physician-scientist in Israel. The CDA supports early-career clinical and translational investigators during their first few years of faculty...
Cancer in My Community: Caring for Children With Cancer in Armenia
Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how providers work to care for people with cancer in their region. Why I Care for People With Cancer When you tell someone that you are a pediatric oncologist and treat children with cancer, the first...
Addition of Venetoclax to Azacitidine in Acute Myeloid Leukemia
In the phase III VIALE-A trial reported in The New England Journal of Medicine, Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and colleagues found that venetoclax plus azacitidine significantly improved overall survival vs azacitidine alone in previously...
Good Outcomes With PET-Directed Therapy for Limited-Stage Diffuse Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, of the University of Arizona Cancer Center, Tucson, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in...
I’ve Turned My Pain Into a New Life Purpose
The first half of 2016 was arguably the most exciting of my life. My wife, Jaione, and I had decided to leave the United Kingdom and move with our two children, Andrew, then 14, and Alba, then 10, to Denver, where I was taking on a leadership role in corporate affairs for a brewery company. By the...
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
On July 24, 2020, brexucabtagene autoleucel, a CD19-directed genetically modified autologous T-cell immunotherapy, was granted accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.1,2 Brexucabtagene autoleucel is approved with a Risk Evaluation...
Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies
Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen...
Corticosteroids Improve Survival in Critically Ill Patients With COVID-19, According to International Trial
In a demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in 8 countries to find that inexpensive, widely available steroids may improve the odds that very sick patients with COVID-19 will survive the illness. The findings were made through the Randomized...
Azacitidine Tablets for Continued Treatment in Acute Myeloid Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 1, 2020, azacitidine tabletswere approved...
The New Face of Medical Visits
“Good morning! I’m Dr. Saksena. It’s a pleasure to meet you.” I wave my introduction as I enter the room. Two women sit beside each other. One of them wears a mask that reads “lipstick optional,” and the other dons a surgical mask. This is a new visit for breast cancer, but I haven’t yet deciphered ...
Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this...
Dr. Kantarjian Shares His Thoughts on Optimizing the Treatment of Adults With ALL
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor and...
Immune Checkpoint Inhibitor Therapy May Contribute to Arterial Inflammation
According to findings from a small study published by Calabretta et al in Circulation, treatment with immune checkpoint inhibitors may worsen inflammation in the arteries that distribute blood from the heart. The research found increased inflammation in the large arteries of 20 Austrian patients...
Cryopreservation May Be Associated With Loss of Quality in Donor Stem Cell Products
During the COVID-19 pandemic, many stem cell transplant centers (including guidance from the National Marrow Donor Program [NMDP]) recommend that stem cell products be frozen for preservation. However, findings from a study by Duncan Purtill, MD, and colleagues in Blood Advances suggest that the...
Theodore Laetsch, MD, Joins Children’s Hospital of Philadelphia to Launch Very Rare Malignant Tumors Program
Pediatric hematologist-oncologist Theodore Laetsch, MD, has joined the Division of Oncology at Children’s Hospital ofPhiladelphia (CHOP), where he will launch a cutting-edge Very Rare Malignant Tumors Program that will seek to develop new treatments for children with rare and complex tumors. In...
Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the antibody-drug conjugate belantamab mafodotin-blmf was granted accelerated approval for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, ...
Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
On July 7, 2020, an oral combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine was approved for treatment of adult patients with myelodysplastic syndromes (MDS), including: Previously treated and untreated, de novo, and secondary MDS with the ...
Global Oncology Young Investigator Award: Early Support Improves Cancer Care Around the World
Global oncology refers to the application of the concepts of global health to cancer and implies an approach to the practice of oncology that acknowledges the reality of limited resources in parts of the world. The Global Oncology Young Investigator Award (YIA) from ASCO and Conquer Cancer, the...
Fitness-Based Treatment of Older Adults With Multiple Myeloma Who Are Transplant-Ineligible: The Changing Landscape
Multiple myeloma is a malignant clonal plasma cell malignancy that primarily affects older adults. Although therapeutic advances have led to improvements in disease-specific and overall survival over the past decade, age-related survival disparities continue to exist. The higher prevalence of...
Avelumab in Maintenance Treatment of Urothelial Carcinoma
On June 30, 2020, avelumab was approved for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.1,2 Supporting Efficacy Data Approval was based on findings in the randomized, multicenter, ...
Large Study Finds No Link Between Antihypertensives and Cancer
There appears to be no evidence that blood pressure–lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic, which was presented at the European Society of Cardiology Congress 2020.1 “Our results should reassure the public about the safety of...
High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
Primary Prevention Strategies for Avoiding Cardiotoxicity in Patients With Cancer: A Growing Area of Research
Cancer is not for the faint of heart, and sometimes neither is the treatment, according to information presented during the ASCO20 Virtual Education Program.1 Approximately 30% of patients who receive cancer therapy will have cardiovascular complications.2 What’s more, in anthracycline-treated...
Update on Novel Immunotherapies for Plasma Cell Disorders
In this installment of The ASCO Post’s Hematology Expert Review, we take a closer look at the monoclonal antibody targeting CD38, daratumumab, in the treatment of amyloid light chain (AL) amyloidosis and resistant multiple myeloma as well as the antibody-drug conjugate belantamab mafodotin-blmf,...
Messino Cancer Centers Founder Michael Messino, MD, Receives North Carolina Governor’s Award
Messino Cancer Centers, a partner practice of American Oncology Network, announced that medical oncologist Michael Messino, MD, has received the highest award granted by North Carolina’s Office of the Governor. The Order of the Long Leaf Pine is presented to individuals who have shown extraordinary ...
Study Indicates Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients
A team of cellular-therapy specialists from Roswell Park Comprehensive Cancer Center has found that patients who develop cytomegalovirus (CMV) infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system, and reduce...
How Delays in Screening and Early Cancer Diagnosis Amid the COVID-19 Pandemic May Result in Increased Cancer Mortality
Earlier this year, as the COVID-19 pandemic was spreading across the United States, federal health officials and cancer societies urged Americans to delay routine cancer screenings and other elective procedures to keep them out of clinics to avoid potential exposure to the coronavirus and to...
Fine-Tuning CAR T-Cell Therapy for Lymphomas
Chimeric antigen receptor (CAR) T-cell therapies are a major advance in the treatment of hematologic malignancies and are making inroads in solid tumors, but there is room for improvement in their design, since not all patients respond, and those who do may relapse. Researchers are studying...
FDA Pipeline: Priority Reviews in Multiple Myeloma, Metastatic Breast Cancer, and NSCLC
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for the treatment of refractory multiple myeloma, metastatic breast cancer, and metastatic non–small cell lung cancer (NSCLC); gave Fast Track designation to treatments for NTRK mutation–positive solid tumors...
TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy
The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent chemotherapy, French investigators reported in an abstract presented during the ASCO20 Virtual Scientific Program.1 The results of the phase II TROPHIMMUN trial ...
Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
FDA Approves Oral Azacitidine as Maintenance Therapy for Adults With AML in First Remission
On September 1, the U.S. Food and Drug Administration (FDA) approved oral azacitidine (Onureg; also known as CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery...
Impact of Prior Insurance Coverage Disruptions on Health-Care Access and Affordability for Currently Insured Cancer Survivors
A new study from the American Cancer Society has found health insurance coverage disruptions in the prior year led to issues with health-care access and affordability for currently insured cancer survivors. The study was published by Zhao et al in Cancer Epidemiology, Biomarkers & Prevention....
Are Patients With Hematologic Cancers More Vulnerable to the Effects of COVID-19?
A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that, compared with patients who have other malignancies, patients with blood cancers are more vulnerable to the effects of COVID-19 infection. These results were published by Lee et al in The Lancet Oncology. As...
Geriatric Comanagement After Cancer Surgery in Patients Aged 75 and Older
In a single-institution study reported in JAMA Network Open, Shahrokni et al found that postoperative care comanaged by the geriatrics service and surgical service was associated with reduced 90-day postoperative mortality vs care managed by the surgical service alone among patients aged 75 and...
FDA Approves FoundationOne Liquid CDx, a Pan-Tumor Liquid Biopsy Test
On August 28, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test for patients with solid tumors. FoundationOne Liquid CDx is a comprehensive genomic-profiling test that analyzes more than 300 cancer-related genes and multiple...
Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Rogers et al found that the combination of obinutuzumab, ibrutinib, and venetoclax produced high response rates in both treatment-naive and relapsed or refractory chronic lymphocytic leukemia. Study Details A total ...
